
Managing BTK Inhibitor Toxicity and Cardiovascular Risk in CLL
The panelists discussed how safety profiles influence Bruton tyrosine kinase (BTK) inhibitor selection for patients with chronic lymphocytic leukemia (CLL) and cardiovascular disease, emphasizing the absence of head-to-head comparisons among acalabrutinib, zanubrutinib, and pirtobrutinib.
Episodes in this series

The panelists discussed how safety profiles influence Bruton tyrosine kinase (BTK) inhibitor selection for patients with chronic lymphocytic leukemia (CLL) and cardiovascular disease, emphasizing the absence of head-to-head comparisons among acalabrutinib, zanubrutinib, and pirtobrutinib. They noted that all of these agents can cause atrial fibrillation, bleeding, and hypertension and that anticoagulants other than warfarin can often be used after counseling about bleeding risk. They raised concern about arrhythmia with significantly reduced ejection fraction and highlighted the value of cardiology input on ongoing anticoagulant or antiplatelet needs. The panelists also discussed everyday management, including myalgia, nail changes, rash, petechiae, and acalabrutinib headache, which often responds to caffeine or acetaminophen. They described holding BTK inhibition after atrial fibrillation and later resuming it, sometimes at a lower dose. They suggested that recurrent events may warrant a change in class and advised caution about another BTK inhibitor after a major bleed.
Related to this article







